From 2012 to 2015, a multicentre, prospective, cohort study (registered with ClinicalTrials. Gov, number NCT01673022) was carried out in United States with 385 patients enrolled to compare ICG-SLN mapping with gold standard of complete lymphadenectomy in endometrial cancer. With the result that 293 of 385 patients had at least one SLN detected successfully using ICG-SLN mapping, 257 of whom were node negative and 36 were node positive, and 35 of 36 patients had metastatic disease correctly identified in the sentinel lymph node. Therefore, the conclusion came to "a sensitivity to detect node-positive disease of 97.2% and a negative predictive value of 99.6%", which proves the ICG-SLN detection is safe enough to replace lymphadenectomy in endometrial cancer .